載入...
STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer
Trastuzumab‐emtansine (T‐DM1) is an antibody‐drug conjugate that has been approved for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer. Despite the remarkable efficacy of T‐DM1 in many patients, resistance to this therapeutic has emerged as a signif...
Na minha lista:
| 發表在: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6172075/ https://ncbi.nlm.nih.gov/pubmed/30076657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13761 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|